Phase 3 data show treatment with REMICADE® (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the ...
The US Food and Drug Administration (FDA) on Friday unveiled briefing documents that could support the approval of Celltrion’s proposed Remicade (infliximab) biosimilar ahead of next Tuesday’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results